Aging Trial Endpoints: A Role-Based Interpretation Framework Without False Equivalence
An endpoint label tells readers where a measure sits in a trial plan. It does not, by itself, tell them whether the measure is clinically important, whether the…
LongevityNext
Research Notes and Articles
From Preclinical Promise to Human Evidence: How to Read a Longevity Translation Claim
“Translated to humans” can mean exposure, target engagement, biomarker movement, short-term safety or clinical benefit. This evidence-led explainer separates those claims and shows what each result supports—and which…
Autophagy as a Drug Target: Separating Flux, Target Engagement and Clinical Benefit
Autophagic flux, target engagement and clinical benefit are different measurements. Human trials and a named programme illustrate the evidence boundaries.
Resilience Endpoints: Measuring Recovery Without Calling Every Rebound Rejuvenation
Recovery trajectories can reveal information that a resting measurement misses. A useful endpoint still needs a defined stressor, baseline, time course and outcome.
Extracellular Matrix and Aging: From Tissue Mechanics to Translational Evidence
Matrix mechanics and matrix fragments can alter cell behavior in experimental systems. The open question is which mechanisms can support safe human interventions.
Model Organisms in Longevity Research: What Transfers—and What Does Not
Model experiments can establish mechanisms and survival effects under defined conditions. Translation still requires exposure, safety and human outcome evidence.
What an Aging-Drug Claim Must Define: A US Regulatory Evidence Framework
The practical issue is a defined product, population, intended use and benefit-risk case—not whether “aging” is an appealing category label.
Evidence-Based Longevity Clinics: A Framework for Evaluating Services, Claims, and Transparency
A 14-dimension framework for assessing clinic governance, evidence, safety, transparency and claims.
Do We Need Aging Clocks—or Better Answers to Specific Health Questions?
Aging clocks can be useful research instruments without being universal clinical scores. Their value depends on the question, comparator, validation and decision.
Longevity Trial Endpoints: Choosing Between Clinical Outcomes, Function and Biomarkers
Clinical events, function, resilience and biomarkers answer different questions. A layered trial design must preserve the distinction between clinical benefit and biological response.